Cliff Asness's HALO Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 1.16 M shares of Halozyme Therapeutics, Inc. (HALO) worth $77.96 M, representing 0.04% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 53 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in HALO, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 589,711 shares. Largest reduction occurred in Q1 2016, reducing 61,148 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +189,848 | Add 19.60% | 1.16 M | $67.30 |
| Q3 2025 | +589,711 | Add 155.68% | 968,511 | $73.34 |
| Q2 2025 | +345,662 | Add 1043.10% | 378,800 | $52.02 |
| Q1 2025 | -19,819 | Reduce 37.42% | 33,138 | $63.81 |
| Q4 2024 | +432 | Add 0.82% | 52,957 | $47.81 |
| Q3 2024 | +4,752 | Add 9.95% | 52,525 | $57.24 |
| Q2 2024 | +2,265 | Add 4.98% | 47,773 | $52.36 |
| Q1 2024 | +502 | Add 1.12% | 45,508 | $40.68 |
| Q4 2023 | -5,257 | Reduce 10.46% | 45,006 | $36.96 |
| Q3 2023 | -6,655 | Reduce 11.69% | 50,263 | $38.20 |
| Q2 2023 | -5,406 | Reduce 8.67% | 56,918 | $36.07 |
| Q1 2023 | -1,444 | Reduce 2.26% | 62,324 | $38.19 |
| Q4 2022 | +5,431 | Add 9.31% | 63,768 | $56.90 |
| Q3 2022 | +4,137 | Add 7.63% | 58,337 | $39.55 |
| Q2 2022 | -3,288 | Reduce 5.72% | 54,200 | $44.00 |
| Q1 2022 | -1,906 | Reduce 3.21% | 57,488 | $39.89 |
| Q4 2021 | -4,454 | Reduce 6.98% | 59,394 | $40.21 |
| Q3 2021 | -7,404 | Reduce 10.39% | 63,848 | $40.67 |
| Q2 2021 | -2,581 | Reduce 3.50% | 71,252 | $45.42 |
| Q1 2021 | -1,581 | Reduce 2.10% | 73,833 | $41.69 |
| Q4 2020 | -16,542 | Reduce 17.99% | 75,414 | $42.71 |
| Q3 2020 | -12,246 | Reduce 11.75% | 91,956 | $26.28 |
| Q2 2020 | +19,836 | Add 23.51% | 104,202 | $26.81 |
| Q1 2020 | -33,804 | Reduce 28.61% | 84,366 | $17.99 |
| Q4 2019 | -18,409 | Reduce 13.48% | 118,170 | $17.73 |
| Q3 2019 | -147 | Reduce 0.11% | 136,579 | $15.51 |
| Q2 2019 | -617 | Reduce 0.45% | 136,726 | $17.18 |
| Q1 2019 | +958 | Add 0.70% | 137,343 | $16.10 |
| Q4 2018 | -35,388 | Reduce 20.60% | 136,385 | $14.63 |
| Q1 2018 | +8,948 | Add 5.50% | 171,773 | $19.59 |
| Q4 2017 | +48,577 | Add 42.52% | 162,825 | $20.26 |
| Q3 2017 | +90,500 | Add 381.08% | 114,248 | $17.37 |
| Q2 2017 | +8,202 | Add 52.76% | 23,748 | $12.80 |
| Q4 2016 | -83 | Reduce 0.53% | 15,546 | $9.84 |
| Q2 2016 | -10,282 | Reduce 39.68% | 15,629 | $8.64 |
| Q1 2016 | -61,148 | Reduce 70.24% | 25,911 | $9.46 |
| Q4 2015 | -9,171 | Reduce 9.53% | 87,059 | $17.33 |
| Q3 2015 | -9,212 | Reduce 8.74% | 96,230 | $13.43 |
| Q2 2015 | +71,842 | Add 213.82% | 105,442 | $22.58 |
| Q1 2015 | +13,200 | Add 64.71% | 33,600 | $14.26 |
| Q4 2014 | -28,155 | Reduce 57.99% | 20,400 | $9.66 |
| Q3 2014 | -16,400 | Reduce 25.25% | 48,555 | $9.10 |
| Q2 2014 | -47,800 | Reduce 42.39% | 64,955 | $9.88 |
| Q1 2014 | +12,300 | Add 12.24% | 112,755 | $12.70 |
| Q4 2013 | +80,055 | Add 392.43% | 100,455 | $14.99 |
| Q2 2013 | +20,400 | Add 0.00% | 20,400 | $7.94 |
| Q4 2012 | +26,049 | Add 0.00% | 26,049 | $6.72 |
Cliff Asness's Halozyme Therapeutics Investment FAQs
Cliff Asness first purchased Halozyme Therapeutics, Inc. (HALO) in Q4 2012, acquiring 26,049 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Halozyme Therapeutics, Inc. (HALO) for 53 quarters since Q4 2012.
Cliff Asness's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q3 2025, adding 968,511 shares worth $71.03 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 1,158,359 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $77.96 M.
As of the Q4 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.04% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Halozyme Therapeutics, Inc. (HALO) was 1,158,359 shares, as reported at the end of Q4 2025.